Daily Bulletin

Men's Weekly

.

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically

- Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma

MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular...

Read more: PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant...

Business News

Why Careers In The Defence Industry Are Growing Rapidly

The defence sector has evolved far beyond traditional roles, opening doors to a wide range of opportunities across technology, engineering, intelligence, and operations. This is where defense industry...

Daily Bulletin - avatar Daily Bulletin

Strategic partnerships to enable global acceleration for Aussie fashion brands: SHEIN Xcelerator launches

SHEIN Xcelerator is introducing a more agile, demand-led operating model, allowing brands to scale while retaining control over creative direction and identity. For fashion brands, the pressure t...

Daily Bulletin - avatar Daily Bulletin

Tips for Avoiding Probate Delays

Probate can be a lengthy process at the best of times, and delays often compound the stress that comes with managing a loved one's estate. Many of those delays are avoidable with the right preparati...

Daily Bulletin - avatar Daily Bulletin